FDA clears Regeneron's Livsayis, a gMG shot dosed four times a year
Regeneron won FDA approval for Livsayis (cemdisiran), the first siRNA therapy approved for generalized myasthenia gravis and the only gMG treatment dosed subcutaneously four times a year. The green light rests on Phase 3 NIMBLE data showing fast, deep symptom control that held steady between quarterly shots. It's also Regeneron's first approved siRNA therapy and its first neurology medicine.
- 2 sources report it: finance.yahoo.com, neurologylive.com.
- The source published it on Nov 18, 2026 at 3:03 PM.
Nothing open. Every check passed.
The FDA approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive, the most common form of the disease, Regeneron announced on Nov. 18. The company says it is the first and only siRNA therapy approved in gMG, and the only FDA-approved gMG treatment given subcutaneously four times a year. It also marks a double first for Regeneron: the company's first approved siRNA therapy and its first neurology medicine. The announcement came via a paid press release distributed by GlobeNewswire.
Livsayis is a C5-directed small interfering RNA therapeutic. It works by reducing levels of circulating complement component factor 5 protein, which limits terminal complement activation, a key driver of gMG. Instead of frequent infusions, patients get a shot every three months.
The approval leans on the Phase 3 NIMBLE trial, where Livsayis posted a 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living total score at 24 weeks, compared with a 2.2-point improvement on placebo. That worked out to a placebo-adjusted improvement of 2.3 points (p=0.0005). The share of MG-ADL responders with at least a 3-point improvement hit 76.6% on Livsayis versus 44.1% on placebo (p<0.001). MG-ADL tracks daily functions like talking, chewing, swallowing, breathing, vision and mobility.
On the Quantitative Myasthenia Gravis scale, which measures muscle function including vision, speaking and swallowing, breathing and limb mobility, Livsayis delivered a 4.2-point improvement at 24 weeks against 1.5 points for placebo, a placebo-adjusted gain of 2.8 points (p=0.0015). QMG responders with at least a 5-point improvement reached 48.4% versus 19.0% on placebo (p<0.001). Patients showed a clinically meaningful MG-ADL benefit of 2.5 points as early as two weeks in, deepening over time, and scores held through 24 weeks with no sign of waning efficacy.
Tuan Vu, M.D., professor of neurology at the University of South Florida Morsani College of Medicine and a global principal investigator of NIMBLE, pointed to the daily toll of the disease. People with gMG face unpredictable muscle weakness and fatigue, plus exacerbations that can be life-threatening, he said, and many still get suboptimal control. Vu called the NIMBLE results evidence that a first-of-its-kind approach targeting a key disease driver can offer a compelling option, with rapid, deep control maintained through the end of each dosing interval.
TopicsRegeneron Pharmaceuticals · LIVSAYIS · cemdisiran · FDA · Tuan Vu · NIMBLE trial · NASDAQ: REGN · generalized myasthenia gravis
Written by AI from verified reporting.
More stories
- Health & science cardiovascularbusiness.com 0 viewsFDA moves to yank liquid statin FloLipid off US shelves
- Health & science cnbc.com Caught by @bayu.lestari45 0 viewsFDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant
- Health & science x.com 0 viewsAdults Ask About Another Measles Shot as US, Mexico and Bolivia Lose Elimination Status
- Health & science finance.yahoo.com 1 viewIonis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides

